



Supplementary Figure 2: Combination of trametinib and vincristine reduces tumor weight. KRAS-mutant PDXs (C1117, C1138, and B8239) were grown subcutaneously in nude mice, which were treated with vehicle (C), trametinib (T), vincristine (V), or a combination (T+V). **(A)** Representative images show tumors harvested at the end of the experiments. Only 5 PDXs shown for C1138. For detailed explanation see Methods. **(B)** Graphs of the weights of harvested tumors. Each dot represents a single tumor. [“Boxes and whiskers represent mean \pm standard deviation.”] *P* values represent T+V vs. all other treatments; *P* < 0.05 was considered significant.